| Literature DB >> 26795276 |
Yasser A Elnakady1,2, Indranil Chatterjee3, Markus Bischoff3, Manfred Rohde4, Michaele Josten5, Hans-Georg Sahl5, Mathias Herrmann3, Rolf Müller1.
Abstract
PURPOSE: The emergence of bacteria that are resistant to many currently used drugs emphasizes the need to discover and develop new antibiotics that are effective against such multi-resistant strains. Kendomycin is a novel polyketide that has a unique quinone methide ansa structure and various biological properties. This compound exhibits strong antibacterial activity against Gram-negative and Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Despite the promise of kendomycinin in several therapeutic areas, its mode of action has yet to be identified.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26795276 PMCID: PMC4721675 DOI: 10.1371/journal.pone.0146165
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Effect of kendomycin on growth of S. aureus strain COL.
Bacterial cultures were grown aerobically in BHI medium, and the optical densities at 600 nm of the cultures were measured at the time points indicated. Kendomycin addition is displayed by vertical arrows. Negative controls (■) were challenged with the solvent methanol at concentrations equivalent to the highest concentration added via the kendomycin supplementation. A) Effect of different kendomycin concentrations on growth of strain COL: 0.5 x MIC (●), 1x MIC (▲), and 3 x MIC (▼). The data presented are the mean ± SD of three independent experiments. B) Impact of kendomycin on the long-term growth characteristic of the S. aureus COL cell culture. BHI cultures of strain COL were grown for up to 24 h in absence (■) or presence of 3 x MIC kendomycin (●). The data presented are the mean ± SD of three independent experiments. C) Effect of kendomycin supplementation on the viability of the COL cell culture. Mid-exponential growth phase cells were either left untreated or challenged with 1.5 x MIC of kendomycin (●), and grown as outlined before. The number of viable bacteria were determined at the time points indicated by plating out serial dilutions of the cultures on agar plates. The data presented are the mean ± SD of two independent experiments.
Fig 2Effects of Kendomycin on the synthesis of macromolecules.
The radioactive labeled precursors 3H-glucosamine (A), 14C-isoleucine (B), 14C-thymidin (C), and 3H-uridin (D) were added to an exponential growth phase culture of S. aureus strain COL in absence (■) and presence (●) of kendomycin (5 x MIC). Incorporation of labeled substances was determined as outlined in materials and methods. The data presented are the mean ± SD of two independent experiments.
DIGE experimental design.
| Gel-Nr. | Cy3 | Cy5 | Cy2 |
|---|---|---|---|
| 1 | Untreated 1 | Treated 3 | Pooled STD |
| 2 | Untreated2 | Treated 4 | Pooled STD |
| 3 | Untreated 1 | Treated 3 | Pooled STD |
| 4 | Untreated 2 | Treated 4 | Pooled STD |
*Pooled STD is an internal standard containing equal amounts of treated and untreated proteins from all samples in the experiment.
Proteins that have been regulated after treatment of S. aureus COL cells with kendomycin.
| Spot No. | Master no | Gene | Identified Protein | TheoreticalMWt | TheoreticalpI | Peptide count | Mascot score | Protein Score C.I. % | Average ratio |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 1264 | Glyceraldehyde3-phosphate dehydrogenase | 37141 | 5.95 | 17 | 228 | 100 | -2.6 | |
| 2 | 779 | Urocanatehydratase | 60854 | 5.23 | 16 | 157 | 100 | -2.54 | |
| 3 | 1259 | Glyceraldehyde3-phosphate dehydrogenase | 37141 | 5.95 | 11 | 160 | 100 | -2.43 | |
| 4 | 769 | Urocanatehydratase | 60854 | 5.23 | 10 | 82 | 97 | -2.38 | |
| 5 | 862 | Phosphoenolpyruvatecarboxykinase | 59511 | 5.74 | 22 | 234 | 100 | -2.28 | |
| 6 | 1263 | Glyceraldehyde3-phosphate dehydrogenase | 37151 | 5.89 | 8 | 106 | 100 | -2.27 | |
| 7 | 849 | Phosphoenolpyruvatecarboxykinase | 59511 | 5.74 | 9 | 99 | 100 | -2 | |
| 8 | 851 | Phosphoenolpyruvatecarboxykinase | 59510 | 5.89 | 22 | 206 | 100 | -1.91 | |
| 9 | 1300 | Glyceraldehyde3-phosphate dehydrogenase | 37151 | 5.89 | 16 | 194 | 100 | -1.89 | |
| 10 | 1257 | Glyceraldehyde3-phosphate dehydrogenase | 37141 | 5.95 | 13 | 144 | 100 | -1.83 | |
| 11 | 1198 | HP | Putative RNA methylasefamily (SACOL1483) | 43621 | 5.07 | 12 | 139 | 100 | -1.81 |
| 12 | 840 | Formate-tetrahydrofolateligase | 60017 | 5.76 | 11 | 145 | 100 | -1.66 | |
| 13 | 599 | Threonyl-tRNAsynthetase | 74455 | 5.26 | 23 | 189 | 100 | -1.59 | |
| 14 | 842 | Formate-tetrahydrofolateligase | 60017 | 5.76 | 16 | 192 | 100 | -1.59 | |
| 15 | 1068 | Elongationfactor Tu | 43134 | 4.74 | 22 | 327 | 100 | -1.59 | |
| 16 | 332 | Alpha-ketoglutaratedecarboxylase | 103104 | 5.47 | 15 | 135 | 100 | -1.58 | |
| 17 | 2109 | Penicillin-bindingprotein 2' | 24250 | 6.96 | 11 | 145 | 100 | -1.58 | |
| 18 | 589 | Threonyl-tRNAsynthetase | 74455 | 5.26 | 14 | 106 | 100 | -1.57 | |
| 19 | 930 | Inosine-5'-monophosphate dehydrogenase | 52904 | 5.61 | 9 | 90 | 99 | -1.57 | |
| 20 | 936 | Inosine-5'-monophosphate dehydrogenase | 52904 | 5.61 | 23 | 273 | 100 | -1.52 | |
| 21 | 766 | Acetyl-CoAsynthetase | 64593 | 5.1 | 12 | 119 | 100 | -1.51 | |
| 22 | 671 | Oligoendopeptidase F | 69890 | 5.14 | 19 | 187 | 100 | -1.5 | |
| 23 | 965 | Glycerolkinase | 55804 | 4.94 | 25 | 386 | 100 | -1.5 | |
| 24 | 1121 | Elongationfactor Tu | 43134 | 4.74 | 22 | 304 | 100 | -1.5 | |
| 25 | 850 | 1-pyrroline-5-carboxylate dehydrogenase | 57003 | 4.98 | 26 | 405 | 100 | 1.5 | |
| 26 | 507 | Formateacetyltransferase | 85264 | 5.31 | 21 | 249 | 100 | 1.54 | |
| 27 | 1883 | Acetoinreductase | 27256 | 5.04 | 8 | 109 | 100 | 1.6 | |
| 28 | 611 | N-acetylmuramoyl-L-alanine amidase | 69239 | 5.96 | 21 | 211 | 100 | 1.64 | |
| 29 | 1274 | ATP:guanidophosphotransferase | 38699 | 5.09 | 9 | 120 | 100 | 1.64 | |
| 30 | 506 | Formateacetyltransferase | 85264 | 5.31 | 22 | 243 | 100 | 1.71 | |
| 31 | 865 | | Nicotinatephosphoribosyltransferase | 54934 | 5.7 | 17 | 214 | 100 | 1.77 |
| 32 | 978 | | pyridinenucleotide-disulfideoxidoreductase | 48500 | 5.54 | 11 | 127 | 100 | 1.86 |
| 33 | 733 | ChaperoninGroEL | 56263 | 4.61 | 14 | 184 | 100 | 1.89 | |
| 34 | 861 | Catalase | 58457 | 5.27 | 33 | 465 | 100 | 1.9 | |
| 35 | 739 | ChaperoninGroEL | 57579 | 4.56 | 25 | 250 | 100 | 1.97 | |
| 36 | 775 | Succinatedehydrogenaseflavoproteinsubunit | 65633 | 5.4 | 21 | 196 | 100 | 1.97 | |
| 37 | 847 | Sucrose-6-phosphate hydrolase | 58009 | 5.16 | 9 | 90 | 99 | 2 | |
| 38 | 645 | DnaKprotein | 66364 | 4.63 | 11 | 87 | 99 | 2.07 | |
| 39 | 2132 | HP | Putative nitroreductasedomain (SACOL2020) | 23988 | 5.41 | 6 | 90 | 99 | 2.12 |
| 40 | 974 | Pyridinenucleotide-disulfideoxidoreductase | 48500 | 5.54 | 10 | 135 | 100 | 2.21 | |
| 41 | 1364 | HP | SACOL0409 | 39147 | 6.09 | 7 | 104 | 100 | 2.21 |
| 42 | 2094 | ATP-dependentClpprotease | 21557 | 5.13 | 8 | 86 | 99 | 2.23 | |
| 43 | 1661 | HeatshockproteinGrpE | 23994 | 4.42 | 7 | 132 | 100 | 2.29 | |
| 44 | 1630 | HeatshockproteinGrpE | 23994 | 4.42 | 8 | 115 | 100 | 2.45 | |
| 45 | 750 | HeatshockproteinGrpE | 56263 | 4.61 | 23 | 284 | 100 | 2.49 | |
| 46 | 740 | ChaperoninGroEL | 56263 | 4.61 | 16 | 180 | 100 | 2.58 | |
| 47 | 647 | DnaKprotein | 66364 | 4.63 | 25 | 320 | 100 | 2.96 | |
| 48 | 447 | Clp ATPase C | 91069 | 5.51 | 16 | 195 | 100 | 4.01 | |
| 49 | 663 | DnaKprotein | 66364 | 4.63 | 20 | 288 | 100 | 4.19 | |
| 50 | 449 | Clp ATPase C | 91069 | 5.51 | 36 | 393 | 100 | 5.04 | |
| 51 | 997 | Metallo-beta-lactamase family protein | 49700 | 5.64 | 7 | 85 | 98 | 5.35 | |
| 52 | 1997 | Azoreductase | 23350 | 4.95 | 11 | 142 | 100 | 5.38 | |
| 53 | 2292 | HP | Putative YceI-like domain protein | 18643 | 4.74 | 12 | 184 | 100 | 5.93 |
| 54 | 441 | Clp ATPase C | 91069 | 5.51 | 19 | 172 | 100 | 5.99 | |
| 55 | 452 | Clp ATPase C | 91069 | 5.51 | 39 | 398 | 100 | 6.17 | |
| 56 | 1035 | Metallo-beta-lactamase family protein | 49551 | 5.61 | 7 | 99 | 100 | 6.34 | |
| 57 | 499 | ClpATPaseB | 98357 | 4.97 | 24 | 193 | 100 | 6.53 | |
| 58 | 536 | ClpATPaseB | 98357 | 4.97 | 19 | 171 | 100 | 6.59 | |
| 59 | 357 | Clp ATPase C | 98385 | 4.97 | 34 | 318 | 100 | 6.88 | |
| 60 | 353 | Clp ATPase B | 98357 | 4.97 | 17 | 121 | 100 | 7.55 | |
| 61 | 500 | Clp ATPase B | 98357 | 4.97 | 32 | 299 | 100 | 10.29 |
Fig 3Effect of kendomycin on the transcription of selected genes in S. aureus COL.
S. aureus COL cells were grown in BHI medium to mid-exponential growth phase, and subsequently supplemented with kendomycin (1.5 x MIC, white bars) or left untreated (black bars). One hour after drug addition, cells were harvested and used for total RNA isolation. A) Transcription of the heat shock protein encoding genes clpC, clpB and clpP. B) Transcription of the capsule operon genes cap5A and cap8C, the UDP-N-acetylglucosamine1-caboxyphenyltransferase encoding gene murAA, and the septum formation factors encoding genes ftsA and ftsZ. C) Transcription of the programmed cell death factor encoding genes cidA and lrgA. D) Transcription of the SigmaB activity marker gene asp23. E) Transcription of the H2O2 inactivating factor encoding genes ahpC and katA. mRNA levels are expressed relative to gyrase B (in numbers of copies per copy of gyrB). The data presented are the mean ± SD of four independent experiments.
Fig 4Effect of kendomycin on the cell division in S. aureus COL.
Electron microscopic images of healthy control cells (A, B) and kendomycin treated cells (C-F). (A) Dividing control cells at the mid of septum formation. (B) Dividing cells with a completed septum. (C-F)Kendomycin treated cells exhibiting irregular septum morphologies. Bar = 200 nm.
Fig 5Glucose and acetate contents in the supernatants of growing S. aureus COL cultures.
A) Consumption of glucose in the presence (●) and absence (■) of kendomycin. B) Accumulation/consumption of acetate in the presence (●) and absence (■) of kendomycin. Arrows indicate the addition of kendomycin. The data presented are the mean ± SD of three independent experiments.
Nucleotide sequences of forward and reverse primers that have been used for real time PCR.
| No. | Gene | Nucleotide sequence of Forward primer | Nucleotide sequence of reverse primer |
|---|---|---|---|
| 1 | 5’-AGTAGCAGTTAGTGAGCCTGATG-3’ | 5’-TCTATCTTGAATACGCACACCATG-3’ | |
| 2 | 5’-GAAGAAGCAATTCGTTTAAATCATTCA-3’ | 5’-CTTTCTAATACTTTTGCAGCAATTCCTT-3’ | |
| 3 | 5’-TGACAACGTAGCAAATTCAATCGTAT-3’ | 5’-CACTTCCACCTGGTGAATTAATGTAT-3’ | |
| 4 | 5’-CGTAGTATGCTTCTATCCTGCTGACTT-3’ | 5’-CATTTACGCCTAATTTTTGTAATTCTT-3’ | |
| 5 | 5’-GCTGCTGAAATTATAGCTACAGAT -3’ | 5’-TACTTGAATATACATTGTCCATTT -3’ | |
| 6 | 5’-TCGCAGTCATTATCATAGGAACATGT-3’ | 5’-AAGCGTCTACACCTTTACGATGTTTAT-3’ | |
| 7 | 5’-ATAACATTGCGTTACTCTTCGTACCA -3’ | 5’-TTGTTGAGACGATTATTAGTCCAATGA-3’ | |
| 8 | 5’-TAGATGAGGTGTCAAAGGACTTAAATGATA-3’ | 5’-AGTTGCGTATTTTCTTGGTTTGTAATT-3’ | |
| 9 | 5’-TAACATCACATCACTTACATCCTCGATA-3’ | 5’-GTGCTTGTACTTCCTCTAAGCTTTCA-3’ | |
| 10 | 5’-CATCTTTATTAGCTTCTGATAAACCGAGT-3’ | 5’-TGTATGTAACGTCAGCATTTAAAGTTGTT-3’ | |
| 11 | 5’- CCACGGAATGAATAATGTTGAATTT -3’ | 5’- GTGTTAATTTTTCACCGATTTGGAT -3’ | |
| 12 | 5’- GGATACAGAAATCAACGGTTCACATAT -3’ | 5’- TATAAAACGAATCGGGAACACATTAAT -3’ | |
| 13 | 5’-CAAGAACAAAATCAAGAGCCTCAAT-3’ | 5’-CTTCACGTGCAGCGATACCA-3’ |